Thrivent Financial for Lutherans Sells 8,965 Shares of Novo Nordisk A/S (NYSE:NVO)

Thrivent Financial for Lutherans decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 6.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,635 shares of the company's stock after selling 8,965 shares during the period. Thrivent Financial for Lutherans' holdings in Novo Nordisk A/S were worth $11,464,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Victory Capital Management Inc. lifted its stake in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after acquiring an additional 23,223 shares during the period. Norman Fields Gottscho Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock worth $5,482,000 after purchasing an additional 19,870 shares during the period. Bryn Mawr Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after purchasing an additional 30,420 shares in the last quarter. Versant Capital Management Inc purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $86,000. Finally, Talbot Financial LLC bought a new position in Novo Nordisk A/S in the fourth quarter worth about $4,066,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on NVO shares. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Friday, March 21st. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded down $1.86 during midday trading on Wednesday, reaching $71.74. 7,574,144 shares of the company's stock traded hands, compared to its average volume of 5,455,948. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a one year low of $71.62 and a one year high of $148.15. The company has a market cap of $321.94 billion, a price-to-earnings ratio of 21.81, a P/E/G ratio of 0.90 and a beta of 0.42. The stock has a 50 day moving average of $83.01 and a 200 day moving average of $99.94.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.